Bringing deep insights from external stakeholders is critical to maximise the potential of pharmacological and non-pharmacological interventions for patients and those who care for them.
Irrespective of lifecycle stage, from early to late stage development, with HCP or patient communities, we have the skill-set needed to design, develop and deliver in line with your needs. Whether you require input into key development decisions, a better understanding of the evolving treatment landscape, evaluation of clinical data, expertise to co-design educational content or test key messages, we will generate the required insights. This may be a standalone activity or equally establishing a working group for engagement over a longer time period.
We will partner with you to:
Timely, insightful, actionable advice and insights from the patient and / or healthcare expert community, giving you the confidence to make informed decisions, progress your plans or simply co-develop your disease awareness and educational materials.
As part of your annual planning cycle or at any point in the development of your asset/disease portfolio, being thoughtful as to your short, medium and long term approach to external collaborations is critical. Collaborations and partnerships with other stakeholders broadens the scope of what can be achieved for your patient community. As Biopharma you may act as a sponsor, a partner in a broader collaboration with disease consortia, patient advocacy organisations, professional societies or indeed work alongside other Biopharma companies. If you are about to embark on this as part of your planning, whether it’s to build an initial plan or refresh an existing one, we can help.
We will partner with you to:
Development of a 3-5 year fully costed external investment plan based on one or more asset strategies within a disease area, with associated lead and lag impact measures. If required, a core communication plan to support delivery of your engagement strategy.
Listening to and learning from the patients living with or at risk of that condition brings invaluable and sometimes unexpected insights to inform your Medical and Scientific Communications plans. Furthermore, these compelling patient stories can be re-produced for Healthcare Professional and Patient education purposes; ideal for use at scientific congresses, as social media posts, on your website, as email content and / or to enhance engagement by MSLs by bringing the necessary clinical and patient context to scientific data.
Partnership with award winning creative agency to develop educational content tailored for priority channels
Patient voices to inform key decisions and plans, irrespective of the stage of development of your medicine, vaccine or medical device. If required, engaging material for medical and patient education purposes as well as for internal training.
To enable a consistent approach to asset communications whether in development or in-market, it is critical that all written information associated with your asset is clear and consistent in message. Having a unified scientific communications resource which sets out clear communication objectives enables your teams, irrespective of role and function, to engage in a consistent way. The foundation will include details of the overall ‘intent’ for the asset, summary of unmet needs, the current & desired future treatment approaches along with the aspirational value it will bring to patients, caregivers and other prioritised stakeholders. Whether you need a comprehensive communication strategy to prepare the market for launch, or simply to educate on the disease state or new therapy, whether you are embarking on your first communications framework or in the process of refreshing an existing resource, we can help you.
A comprehensive communication strategy and fully referenced narrative(s) comprising of cross-functionally aligned key communication messages. (Optional) proposed communications activity plan for publications, scientific congresses / symposia and field-medical activities, to support story evolution over time.
Medical Society conferences and international congresses are an important channel for communication and discussion on the latest scientific data and evidence, and a key component of any Scientific Communications strategy. Such events also provide the opportunity to learn; unmet medical needs, data gaps, clinical practice, patient journeys etc. With effective pre-event planning unprecedented levels of engagement can be achieved with prioritised stakeholders. Whether your company is new to a therapy area or well-established, we have the knowledge and expertise to ensure you maximise the potential of professional society-organised scientific meetings.
(Optional) schedule of meetings with key stakeholders (KOL delegates / patient group representatives / Medical Society leadership)
A bespoke scientific congressing strategy and plan, relevant to your strategic priorities and budget.
Rapidly build the knowledge and skills to effectively and compliantly educate the speaker community, with a connected and consistent approach across key markets.
Knowledgeable and informed expert available for global and in-country educational or promotional, either as part of your product launch plan or to enhance impact and reach beyond the launch phase.
Whether you are needing to build an entire new team or enhance the effectiveness of an existing one, we bring the relevant expertise to ensure MSLs can communicate impactfully to gain insights, shape management of disease and ultimately improve outcomes for patients.
Knowledgeable, confident and engaged MSLs who are well-practised in communicating scientific data and evidence in a meaningful and impactful manner, together with recommendations on next steps to embed development and high performance over time.
Whether your team are new to organising and delivering advice seeking activities, or requiring a reminder or inspiration to advance their engagement and facilitation skills, we can tailor our offering to meet your needs.
Recommendations to embed capability development over time
Knowledgeable, confident and skilled Medical teams who have the required knowledge and capabilities to plan, develop and deliver advisory group meetings, in-person and / or in virtual settings.
Global Key Opinion Leaders are potentially being engaged by a significant number of individuals, from various functions across a company with medicines / vaccines from early to late-stage development. In particular within large organisations, it is not clear who is engaging who often and for what activity or what the outcomes and next steps are. There is a compliance risk here, with over-reliance on the professional services of a small group of KOLs, as well as potential duplication of effort, wasted budget and missed insights. If you recognise this as a challenge in your business, we can help with our tried and tested integrated engagement planning approach.
(Optional) delivery of briefings for relevant team members
~ 12-15 global expert engagement plans in place, teams engaged and inspired to plan and deliver engagement together and KOLs confident that the company is engaging them in line with global and local regulations on topics and services which will help to advance patient care in that therapy area.
Bringing deep insights from external stakeholders is critical to maximise the potential of pharmacological and non-pharmacological interventions for patients and those who care for them.